HRCM
VRDN icon

Hood River Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Hood River Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-566,498
Closed -$14.4M – 147
2023
Q1 		$14.4M Buy
+566,498
New +$18.2M 0.47% 68

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Hood River Capital Management's VRDN Position: Q2 2023 in Review

Hood River Capital Management sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 566,498 shares — an estimated $14.4M sold.

Hood River Capital Management first reported a position in VRDN in Q1 2023 and held it in 1 quarter. The position peaked at $14.4M in Q1 2023. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • Hood River Capital Management reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Hood River Capital Management sold 566,498 Viridian Therapeutics shares in Q2 2023, an estimated $14.4M.
  • Hood River Capital Management first reported a position in Viridian Therapeutics in Q1 2023 and held it in 1 quarter.
  • Hood River Capital Management's Viridian Therapeutics position peaked at $14.4M in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on Hood River Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.